Plinabulin
Small Cell Lung Carcinoma
Xiaorong DongSmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 81/ 100
Competitive context
276 Active assets in the Small Cell Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benmelstobart Yayi He | Phase 4 | A |
Berzosertib National Cancer Institute (NCI) | Phase 2 | BBB |
Anti-Pd-L1 Monoclonal Antibody Shr-1316 Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | BBB |
Cis-Diamminedichloroplatinum Ii National Cancer Institute (NCI) | Phase 4 | BBB |
Etoposide Sichuan University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Plinabulin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →